Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.3
(0.0%)
HKD 1.3
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 30.94 Million HKD | 219.92% |
| 2022 | -25.8 Million HKD | -148.36% |
| 2021 | -10.39 Million HKD | 95.97% |
| 2020 | -257.82 Million HKD | 57.54% |
| 2019 | -607.18 Million HKD | -103.26% |
| 2018 | -298.72 Million HKD | 14.51% |
| 2017 | -349.4 Million HKD | 5.55% |
| 2016 | -369.92 Million HKD | -13.4% |
| 2015 | -326.2 Million HKD | 4.24% |
| 2014 | -340.64 Million HKD | -10.08% |
| 2013 | -309.44 Million HKD | -2.62% |
| 2012 | -301.53 Million HKD | -160.07% |
| 2011 | -115.94 Million HKD | -15.43% |
| 2010 | -100.44 Million HKD | -132.61% |
| 2009 | -43.18 Million HKD | -215.59% |
| 2008 | -13.68 Million HKD | -768.21% |
| 2007 | -1.57 Million HKD | -122.85% |
| 2006 | 6.89 Million HKD | 160.3% |
| 2005 | 2.65 Million HKD | 146.57% |
| 2004 | -5.69 Million HKD | -237.08% |
| 2003 | 4.15 Million HKD | 173.0% |
| 2002 | -5.68 Million HKD | -162.09% |
| 2001 | 9.15 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | 30.94 Million HKD | 219.92% |
| 2023 Q3 | 25.68 Million HKD | -36.84% |
| 2023 Q4 | 30.94 Million HKD | 20.48% |
| 2023 Q1 | 31.12 Million HKD | 220.6% |
| 2023 Q2 | 40.67 Million HKD | 30.68% |
| 2022 Q3 | 368.04 Million HKD | 377.18% |
| 2022 Q4 | -25.8 Million HKD | -107.01% |
| 2022 FY | -25.8 Million HKD | -148.36% |
| 2022 Q1 | 277.52 Million HKD | 2770.86% |
| 2022 Q2 | -132.78 Million HKD | -147.85% |
| 2021 FY | -10.39 Million HKD | 95.97% |
| 2021 Q1 | 414.53 Million HKD | 260.78% |
| 2021 Q4 | -10.39 Million HKD | 0.0% |
| 2021 Q2 | -117.41 Million HKD | -128.32% |
| 2020 Q4 | -257.82 Million HKD | 0.0% |
| 2020 Q1 | 775.13 Million HKD | 227.66% |
| 2020 Q2 | -425.91 Million HKD | -154.95% |
| 2020 FY | -257.82 Million HKD | 57.54% |
| 2019 Q1 | 429.59 Million HKD | 243.81% |
| 2019 FY | -607.18 Million HKD | -103.26% |
| 2019 Q2 | -638.92 Million HKD | -248.73% |
| 2019 Q4 | -607.18 Million HKD | 0.0% |
| 2018 Q2 | -372.85 Million HKD | -181.9% |
| 2018 FY | -298.72 Million HKD | 14.51% |
| 2018 Q1 | 455.23 Million HKD | 230.29% |
| 2018 Q4 | -298.72 Million HKD | 0.0% |
| 2017 Q1 | 504.97 Million HKD | 236.51% |
| 2017 FY | -349.4 Million HKD | 5.55% |
| 2017 Q4 | -349.4 Million HKD | 0.0% |
| 2017 Q2 | -348.32 Million HKD | -168.98% |
| 2016 FY | -369.92 Million HKD | -13.4% |
| 2016 Q1 | 394.14 Million HKD | 220.83% |
| 2016 Q2 | -310.8 Million HKD | -178.85% |
| 2016 Q4 | -369.92 Million HKD | 0.0% |
| 2015 FY | -326.2 Million HKD | 4.24% |
| 2015 Q2 | -613.14 Million HKD | -256.05% |
| 2015 Q4 | -326.2 Million HKD | 0.0% |
| 2015 Q1 | 392.91 Million HKD | 215.34% |
| 2014 Q1 | 379.06 Million HKD | 222.5% |
| 2014 Q4 | -340.64 Million HKD | 0.0% |
| 2014 FY | -340.64 Million HKD | -10.08% |
| 2014 Q2 | -321.36 Million HKD | -184.78% |
| 2013 Q1 | 333.9 Million HKD | 210.73% |
| 2013 FY | -309.44 Million HKD | -2.62% |
| 2013 Q4 | -309.44 Million HKD | 0.0% |
| 2013 Q2 | -217.71 Million HKD | -165.2% |
| 2012 FY | -301.53 Million HKD | -160.07% |
| 2012 Q2 | -118.96 Million HKD | 0.0% |
| 2012 Q4 | -301.53 Million HKD | 0.0% |
| 2011 FY | -115.94 Million HKD | -15.43% |
| 2011 Q2 | -56.63 Million HKD | 0.0% |
| 2011 Q4 | -115.94 Million HKD | 0.0% |
| 2010 Q2 | -30.91 Million HKD | 0.0% |
| 2010 FY | -100.44 Million HKD | -132.61% |
| 2009 FY | -43.18 Million HKD | -215.59% |
| 2008 FY | -13.68 Million HKD | -768.21% |
| 2007 FY | -1.57 Million HKD | -122.85% |
| 2006 FY | 6.89 Million HKD | 160.3% |
| 2005 FY | 2.65 Million HKD | 146.57% |
| 2004 FY | -5.69 Million HKD | -237.08% |
| 2003 FY | 4.15 Million HKD | 173.0% |
| 2002 FY | -5.68 Million HKD | -162.09% |
| 2001 FY | 9.15 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 111.963% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 98.477% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -420.659% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 89.737% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 262.559% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 114.117% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 87.919% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 91.803% |
| SSY Group Limited | 1.71 Billion HKD | 98.194% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 518.273% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 90.829% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 99.939% |